Skip navigation HCP China

Predictive Biosciences

Predictive Biosciences is developing proprietary biomarker and assay technology for highly accurate, patient-friendly, real-time cancer diagnostics. The company is focused on validating and demonstrating the superior clinical utility of its protein biomarkers and developing products for commercialization across multiple cancer types. Predictive Biosciences was co-founded in 2006 by Marsha A. Moses, Ph.D., Bruce R. Zetter, Ph.D. and Eugene Chiu.

Recent News

Predictive Biosciences to Present at the 102nd AACR Annual Meeting

Predictive Biosciences Features Novel Multiplex PCR Assay for FGFR3 Mutation Detection at the ASCO 2011 Genitourinary Cancers Symposium

Predictive Biosciences Closes $25 Million Series C Financing

Diagnostic Industry Veteran Kim Blickenstaff Joins Predictive Biosciences’ Board of Directors

Predictive Biosciences Announces Acquisition of OncoDiagnostic Laboratory

Predictive Biosciences’ Breast Cancer Biomarker Findings Highlighted in Proceedings of the National Academy of Sciences

Predictive Biosciences Closes $21.75 Million in Series B Financing